EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differential inhibition of intra- and inter-molecular protease cleavages by antiviral compounds

Jennifer S Doherty iD, Karla Kirkegaard iD

Journal of Virology · 2023

DOI: 10.1128/jvi.00928-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2023. Verfasst von Jennifer S Doherty und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Stanford University, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Viral Proteases, Viral Protease Inhibitors, Enterovirus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health, National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enteroviruses encode two protease active sites, in the 2A and 3C coding regions. While they target many host proteins, they first need to be excised from the viral polyprotein in which they are embedded. Polyprotein cleavage can occur either intra-molecularly (in cis ) or inter-molecularly (in trans ). Previous work suggested that antivirals targeting intra-molecular cleavages could generate inhibitory precursors that can suppress the outgrowth of drug-resistant variants. Therefore, we wanted to evaluate enteroviral cleavage patterns to identify such obligate intra-molecular cleavages as a method of drug target selection. Using translation extracts, we show that cis cleavage of the 2A protease N-terminal junction is conserved across three enterovirus clades, while the mechanism for the N-terminal junction of 3C varies, with enterovirus D68 3C cleavage occurring in cis and poliovirus 3C cleavage occurring in trans . Antiviral agents targeting proteases are generally identified via their ability to block the cleavage of artificial peptide substrates. Here, we show that antivirals identified for their ability to block inter-molecular cleavage can sometimes block intra-molecular cleavage of the protease from its polyprotein but with widely varying efficacy. Additionally, we demonstrate that for three enteroviral species, genomes defective in 2A protease activity suppress the growth of wild-type virus in mixed populations, supporting the hypothesis that preventing intra-molecular cleavage at the VP1·2A junction can create dominantly inhibitory precursors. These data argue that, to reduce the likelihood of drug resistance, protease-targeted antivirals should be evaluated for their ability to block intra-molecular polyprotein cleavages in addition to inter-molecular cleavage of other substrates. IMPORTANCE Most protease-targeted antiviral development evaluates the ability of small molecules to inhibit the cleavage of artificial substrates. However, before they can cleave any other substrates, viral proteases need to cleave themselves out of the viral polyprotein in which they have been translated. This can occur either intra- or inter-molecularly. Whether this process occurs intra- or inter-molecularly has implications for the potential for precursors to accumulate and for the effectiveness of antiviral drugs. We argue that evaluating candidate antivirals for their ability to block these cleavages is vital to drug development because the buildup of uncleaved precursors can be inhibitory to the virus and potentially suppress the selection of drug-resistant variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsViral ProteasesViral Protease InhibitorsEnterovirusProteolysisPolyproteins

Stichwörter der Autor:innen

antiviraldrug resistanceenterovirus A71enterovirus D68picornaviruspolioviruspolyproteinpositive-stranded RNA virusproteaseviral genetics

Substanzen

Antiviral AgentsViral ProteasesViral Protease InhibitorsPolyproteins

Autor:innen und Institutionen

  • Department of Genetics, Stanford University, Palo Alto, California, USA.
  • Department of Microbiology and Immunology, Stanford University, Palo Alto, California, USA.

ORCID-Profile: Jennifer S Doherty, Karla Kirkegaard

Förderung

  • NIAID NIH HHS
  • HHS | National Institutes of Health
  • National Science Foundation
  • SU | School of Medicine, Stanford University

Zitieren

APA

Doherty, J. S., & Kirkegaard, K. (2023). Differential inhibition of intra- and inter-molecular protease cleavages by antiviral compounds. Journal of Virology. https://doi.org/10.1128/jvi.00928-23

Vancouver

Doherty JS, Kirkegaard K. Differential inhibition of intra- and inter-molecular protease cleavages by antiviral compounds. Journal of Virology. 2023. doi:10.1128/jvi.00928-23

BibTeX
@article{Doherty2023,
  author = {Doherty, Jennifer S and Kirkegaard, Karla},
  title = {Differential inhibition of intra- and inter-molecular protease cleavages by antiviral compounds},
  journal = {Journal of Virology},
  year = {2023},
  doi = {10.1128/jvi.00928-23}
}
Kostenlos starten →